Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : JNJ crawled time : 20:20 save search
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
Published: 2024-03-09 (Crawled : 20:20) - prnewswire.com
PTGX | $25.61 1.55% 1.52% 450K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
jnj-2113 first year psoriasis one clearance skin
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
Published: 2023-06-03 (Crawled : 20:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
response results study
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
Published: 2023-06-03 (Crawled : 20:20) - prnewswire.com
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $290.38 3.83% 220
|
Health Technology
| Email alert
Add to watchlist
response
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
Published: 2023-04-30 (Crawled : 20:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.06%
H: 0.43%
C: 0.0%
tar-200 antibody bladder cancer results study
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Published: 2023-03-04 (Crawled : 20:20) - prnewswire.com
PVBC | $7.85 1.68% 1.66% 100K
|
Finance
| Email alert
Add to watchlist
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
trial deadline
Global Men's Grooming Products Market Report 2022: A $57.2 Billion Industry in 2021 - Forecasts to 2028 Featuring P&G, Estee Lauder, Unilever, J&J, & Coty Among Others
Published: 2023-01-22 (Crawled : 20:20) - prnewswire.com
PHG | $19.98 0.0% 540K
|
Health Technology
|
| O: 1.51%
H: 3.28%
C: 2.92%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.21%
H: 0.31%
C: -0.47%
EPC 4 | $36.65 1.41% 0.0% 260K
|
Consumer Non-Durables
|
| O: 0.12%
H: 0.47%
C: -1.68%
COTY | $11.15 1.0% 0.0% 6.2M
|
Consumer Non-Durables
|
| O: 0.0%
H: 0.58%
C: 0.53%
global report market
Insights on the Atrial Fibrillation Global Market to 2028: by End-user, Type, Technology and Region
Published: 2023-01-21 (Crawled : 20:20) - prnewswire.com
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
| Email alert
Add to watchlist
ATRC | $23.19 -0.86% -0.86% 470K
|
Health Technology
| Email alert
Add to watchlist
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
PHG | $19.98 0.0% 540K
|
Health Technology
| Email alert
Add to watchlist
global technology market
$12.8 Billion Worldwide Erythropoietin Drugs Industry to 2027 - Featuring Amgen, Biocon, Dr. Reddy's Laboratories and Intas Pharmaceuticals Among Others
Published: 2023-01-21 (Crawled : 20:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
pharmaceuticals
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
faspro darzalex trial
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
Published: 2022-12-10 (Crawled : 20:20) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
meeting therapeutics
Janssen Joins Forces with Pro Football Hall-of-Famer Shannon Sharpe to Address Health Disparities in Prostate Cancer
Published: 2022-09-18 (Crawled : 20:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
health cancer prostate cancer
2022 New Jersey 'Walk with Us to Cure Lupus' Raises Awareness and Funds for Commonly Misdiagnosed Autoimmune Disease
Published: 2022-05-14 (Crawled : 20:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
disease
Aspen presented with 2022 Economic Diplomacy (Global) Ubuntu Award
Published: 2022-02-12 (Crawled : 20:20) - aspenpharma.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
awards
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $290.38 3.83% 220
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
| Email alert
Add to watchlist
results antibody
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
Published: 2021-12-05 (Crawled : 20:20) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
phase 2 covid positive phase 2 results results topline vaccine covid-19
Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2021
Published: 2021-06-05 (Crawled : 20:20) - akaritx.com
FBRX 4 | $0.78 5.13% 8.3K
|
Health Technology
| Email alert
Add to watchlist
ATEC | $12.54 1.62% 1.59% 1.3M
|
Health Technology
| Email alert
Add to watchlist
DB | $15.91 0.7% 0.57% 4.6M
|
Finance
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.